Sepset said its early test for sepsis, a condition that requires rapid diagnosis and treatment, would give clinicians valuable time to identify treatment strategies.
The firm expects to validate its test as a triage tool to identify SARS-CoV-2 patients at risk of sepsis and pursue US FDA Emergency Use Authorization.
The company said it has scaled up production capacity to two million reactions per week and has the potential to scale up to three million reactions per week.
The infectious disease testing firm has developed a sequencing-based coronavirus assay, which it plans to commercialize through its sister firm BioID Genomics.
The diagnostics firm is conducting a 1,000-person study to find T cell profiles associated with the immune response to COVID-19 and recovery from the disease.
With TMB as a CDx, the drug will be available to more patients as a salvage option, but doctors will still need to consider the complex biomarker amid evolving research.
The firm believes that its molecular assay for the laboratory will help ease some of the supply chain issues hampering test rollout during the pandemic.
